Genomic Markers for Measuring Breast Cancer Response to Neoadjuvant Chemotherapy

Official Title

Genomic Markers for Measuring Breast Cancer Response to Neoadjuvant Chemotherapy

Summary:

The primary aim of the study is to identify genomic markers (circulating tumour cells (CTCs), circulating tumour DNA (ctDNA), transcriptomic markers) as biomarkers of response to neoadjuvant chemotherapy (NAC) among patients with invasive breast cancer.

Trial Description

Primary Outcome:

  • Pathologic complete response (pCR)
Secondary Outcome:
  • Time to distant breast cancer recurrence (months)
  • Time to any recurrence (months)
  • Time to death
The study aims to evaluate genetic markers (i.e. CTCs and ctDNA) in breast tumours to predict therapy response and metastatic risk. We aim to investigate genomic markers of treatment response and outcomes in breast cancer patients treated with neoadjuvant chemotherapy. The role of CTCs and ctDNA in predicting response to NAC will also be investigated.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society